An illustration of a hepatitis C virus

A single-injection cure for hepatitis C virus in low- and middle-income countries

While hepatitis C virus (HCV) infection occurs in all global regions, many people living with hepatitis C reside in low- and middle-income countries. The highest burden of disease is in the Eastern Mediterranean region, but numbers are high in the South-East Asia region, European region and the Western Pacific region, with Africa and South American Regions not far behind. The majority of these communities having limited access to life-saving medication due to various complexities in healthcare programmes.

Hepatitis C infection is an inflammation of a person's liver caused by the hepatitis C virus which can cause both acute and chronic hepatitis. The severity of infection can range from a mild illness to a serious, lifelong illness including liver cirrhosis and cancer both of which can lead to death.

The hepatitis C virus is a bloodborne virus most commonly transmitted through the reuse or inadequate sterilization of medical equipment such as syringes and needles in healthcare settings, the transfusion of unscreened blood and blood products, and sharing of injection equipment during drug use.

The World Health Organization stipulate the importance of understanding that hepatitis C is not spread through breast milk, food, water or casual contact such as hugging, kissing and sharing food or drinks with an infected person.

 

Symptoms of hepatitis C virus infection

Most people do not exhibit symptoms in the first few weeks after they are infected. It can take between two weeks to six months to have symptoms, which can include:

  • fever
  • feeling very tired
  • loss of appetite
  • nausea and vomiting
  • dark urine
  • pale faeces
  • joint pain
  • jaundice (yellowing of the skin or eyes).

 

The hepatitis C virus burden

  • Globally, an estimated 50 million people have chronic hepatitis C virus infection, with about 1 million new infections occurring per year. 75% of these cases occur within low- and middle-income countries (LMICs).
  • Approximately 242,000 people died from hepatitis C caused liver diseases; mainly cirrhosis and hepatocellular carcinoma (primary liver cancer)
  • Antiviral medicines can cure more than 95% of people with hepatitis C infection, but access to diagnosis and treatment is low in LMICs.

Source: World Health Organization: Hepatitis C

 

LONGEVITY and hepatitis C

Oral drugs for hepatitis C require an extensive regimen that can be difficult to maintain. Replacing these with a single long-acting injection would cure patients of the hepatitis C virus at the point of diagnosis.

Hepatitis C virus can be cured by taking three daily tablets for eight weeks, amounting to 168 tablets for a full course. A long-acting injectable treatment lasting for 8 weeks or more could equate to a single-injection cure for many patients, providing rapid therapy and eliminating issues around pill burden, complex delivery modes and stigma.

Our highly accessible and simple to administer curative treatment could contribute massively to the target set by The World Health Organisation for global elimination of this virus by 2030.


Read our latest hepatitis C virus blogs

 

Dr Usman Arshad stands on a podium delivering a talk at CROI 2024. The blog title is written over the top

An image with the blog title written over the topA community group are sat closely in conversation. The title of the blog is written over the top.

 

 

 


Back to: Centre of Excellence for Long-acting Therapeutics

Sign up to our newsletter

 

Any personal information you provide will be held in accordance with The EU General Data Protection Regulation (GDPR). For more information please see our Privacy notice

Our funding

The LONGEVITY Project is funded by Unitaid

The Unitaid logo is the organisation name written above the words

The project also involves critical partners and collaborators in the Clinton Health Access Initiative, Johns Hopkins University, Medicines Patent Pool, Tandem Nano Ltd., Treatment Action Group and the University of Nebraska Medical Center

The Clinton Health Access Initiative logo is the name with a ring of stars flying from itJohns Hopkins University logo is the Institution name under its crestThe Medicines Patent Pool logo is the organisation name to the right of three interconnecting circlesThe Tandem Nano Ltd logo is the organisation name to the right of a stylised letter T graphicThe Treatment Action Group logo is the Acronym The UNMC logo is the initialisation with the words